Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 134864
Gene Symbol: TAAR1
TAAR1
0.010 Biomarker group BEFREE Similarly, we discuss localization of TAAR1 expression in the gut, novel findings that TAAR1 may be implicated in inflammatory bowel diseases, and the reported comorbidities of neuropsychiatric disorders and gastrointestinal disorders. 31836967 2020
Entrez Id: 55213
Gene Symbol: RCBTB1
RCBTB1
0.010 GeneticVariation group BEFREE Combination with GLP-1RAs exhibited more HbA1c reduction (WMD: -0.8; 95% CI, -1.14 to -0.45%), weight loss (-1.46; 95% CI, -2.38 to -0.54 kg), and systolic blood pressure (SBP) reduction (-2.88; 95% CI, -4.52 to -1.25 mmHg) versus SGLT2is alone but increased the gastrointestinal disorder risk (RR: 1.68; 95% CI, 1.14-2.47). 31642583 2020
Entrez Id: 79813
Gene Symbol: EHMT1
EHMT1
0.010 GeneticVariation group BEFREE Combination with GLP-1RAs exhibited more HbA1c reduction (WMD: -0.8; 95% CI, -1.14 to -0.45%), weight loss (-1.46; 95% CI, -2.38 to -0.54 kg), and systolic blood pressure (SBP) reduction (-2.88; 95% CI, -4.52 to -1.25 mmHg) versus SGLT2is alone but increased the gastrointestinal disorder risk (RR: 1.68; 95% CI, 1.14-2.47). 31642583 2020
Entrez Id: 342096
Gene Symbol: GOLGA6A
GOLGA6A
0.010 GeneticVariation group BEFREE Combination with GLP-1RAs exhibited more HbA1c reduction (WMD: -0.8; 95% CI, -1.14 to -0.45%), weight loss (-1.46; 95% CI, -2.38 to -0.54 kg), and systolic blood pressure (SBP) reduction (-2.88; 95% CI, -4.52 to -1.25 mmHg) versus SGLT2is alone but increased the gastrointestinal disorder risk (RR: 1.68; 95% CI, 1.14-2.47). 31642583 2020
Entrez Id: 4582
Gene Symbol: MUC1
MUC1
0.010 Biomarker group BEFREE According to this survey, only a minor portion of the 44 medicinal plants considered in EMA monographs for the treatment of gastrointestinal diseases has been studied so far with regard to potential interactions with gut microbiota. 31408679 2019
Entrez Id: 3172
Gene Symbol: HNF4A
HNF4A
0.010 Biomarker group BEFREE In this review, we will update our current understanding on the role of HNF4α in human liver and gastrointestinal diseases. 31435165 2019
Entrez Id: 146206
Gene Symbol: CARMIL2
CARMIL2
0.010 Biomarker group BEFREE This case provides evidence that CARMIL2 should be a candidate gene when diagnosing children with very early onset inflammatory and eosinophilic gastrointestinal disorders, even when signs of immunodeficiency are not observed. 31079270 2019
Entrez Id: 947
Gene Symbol: CD34
CD34
0.010 Biomarker group BEFREE Utility of histology for the diagnosis of portal hypertensive gastroenteropathy. Concordance between the endoscopic image and gastrointestinal biopsies. Role of the CD34 marker. 30459058 2019
Entrez Id: 8929
Gene Symbol: PHOX2B
PHOX2B
0.010 Biomarker group BEFREE Future studies are required to characterise the functions of Phox2b in the adult enteric nervous system and to determine its potential as a therapeutic target in gastrointestinal disorders. 31019703 2019
Entrez Id: 2108
Gene Symbol: ETFA
ETFA
0.010 Biomarker group BEFREE According to this survey, only a minor portion of the 44 medicinal plants considered in EMA monographs for the treatment of gastrointestinal diseases has been studied so far with regard to potential interactions with gut microbiota. 31408679 2019
Entrez Id: 4434
Gene Symbol: MSD
MSD
0.010 Biomarker group BEFREE The present research indicates that 8-MSD may be therapeutically useful as an anti-hypertension agent and to potentially treat cardiovascular and gastrointestinal diseases. 31404616 2019
Entrez Id: 2668
Gene Symbol: GDNF
GDNF
0.010 GeneticVariation group BEFREE Diverticular disease, a major gastrointestinal disorder, is associated with modifications of the enteric nervous system, encompassing alterations of neurochemical coding and of the tyrosine receptor kinase Ret/GDNF pathway. 31019703 2019
Entrez Id: 57511
Gene Symbol: COG6
COG6
0.010 Biomarker group BEFREE COG6-CDG is a rare autosomal recessive disease of congenital disorders of glycosylation (CDG) caused by deficiency of subunit 6 of the conserved oligomeric Golgi complex (COG6), which is characterized by growth retardation, developmental disability, microcephaly, liver and gastrointestinal disease, recurrent infections and hypohidrosis/hyperthermia. 29709711 2019
Entrez Id: 11128
Gene Symbol: POLR3A
POLR3A
0.010 Biomarker group BEFREE Patients with both anti-RPA194 and anti-RPC155 were significantly less likely to have severe gastrointestinal disease than patients with anti-RPC155 only (26.3% versus 51.0%; P = 0.043). 30888702 2019
Entrez Id: 2295
Gene Symbol: FOXF2
FOXF2
0.010 Biomarker group BEFREE The transcription factors FOXF1 and FOXF2 have been implicated in the development of the gastrointestinal tract but their role in adults or in gastrointestinal diseases is poorly understood. 30565344 2019
Entrez Id: 2294
Gene Symbol: FOXF1
FOXF1
0.010 AlteredExpression group BEFREE The transcription factors FOXF1 and FOXF2 have been implicated in the development of the gastrointestinal tract but their role in adults or in gastrointestinal diseases is poorly understood. 30565344 2019
Entrez Id: 25885
Gene Symbol: POLR1A
POLR1A
0.010 Biomarker group BEFREE Patients with both anti-RPA194 and anti-RPC155 were significantly less likely to have severe gastrointestinal disease than patients with anti-RPC155 only (26.3% versus 51.0%; P = 0.043). 30888702 2019
Entrez Id: 10861
Gene Symbol: SLC26A1
SLC26A1
0.010 AlteredExpression group BEFREE The present review gives an overview on the current state of knowledge of the intestinally expressed SLC26A isoforms (SLC26A1,2,3,6,7,9,11) from the history of their functional identification, cloning and expression, the insights into their function, interaction partners and regulation gained in heterologous expression systems and Slc26a-deficient mice, to information about their transcriptional regulation and roles in gastrointestinal disease manifestations.© 2019 American Physiological Society.Compr Physiol 9:839-872, 2019. 30873581 2019
Entrez Id: 5376
Gene Symbol: PMP22
PMP22
0.010 Biomarker group BEFREE <b>Methods:</b> Two established models of experimental colitis, namely chemically-induced DSS colitis and the spontaneous colitis that develops in <i>Muc2</i> deficient mice, were used to assess whether QBECO treatment could ameliorate gastrointestinal disease. 30319652 2018
Entrez Id: 3704
Gene Symbol: ITPA
ITPA
0.010 AlteredExpression group BEFREE No significant association was found between ITPA activity and hepatotoxicity or clinical ADRs such as cutaneous reactions, arthralgia, flulike symptoms and gastrointestinal disorders. 29327413 2018
Entrez Id: 1672
Gene Symbol: DEFB1
DEFB1
0.010 GeneticVariation group BEFREE Alleles, genotypes and/or altered gene expression of its coding gene, DEFB1, have been associated with several human diseases/conditions ranging from metabolic/chronic (e.g. cancer), infectious (e.g. tuberculosis, HIV/AIDS), inflammatory (gastrointestinal diseases), male infertility and more recently, neurologic (e.g. depression and Alzheimer) and autoimmune diseases (e.g. vitiligo and systemic lupus erythematosus). 30236992 2018
Entrez Id: 50616
Gene Symbol: IL22
IL22
0.010 Biomarker group BEFREE IL-22 is the most intensively studied cytokine within this family in contexts of gastrointestinal disease, but the importance of other family members is more and more appreciated. 29967613 2018
Entrez Id: 5873
Gene Symbol: RAB27A
RAB27A
0.010 Biomarker group BEFREE Astragalus membranaceus (Radix Astragali, RA) and Atractylodes macrocephala (Rhizoma Atractylodis Macrocephalae, RAM) are often used to treat gastrointestinal diseases. 30269844 2018
Entrez Id: 5919
Gene Symbol: RARRES2
RARRES2
0.010 Biomarker group BEFREE Diagnostic value of chemerin in lower gastrointestinal diseases-a review. 30165089 2018
Entrez Id: 190
Gene Symbol: NR0B1
NR0B1
0.010 Biomarker group BEFREE <b>Methods:</b> Two established models of experimental colitis, namely chemically-induced DSS colitis and the spontaneous colitis that develops in <i>Muc2</i> deficient mice, were used to assess whether QBECO treatment could ameliorate gastrointestinal disease. 30319652 2018